Three-dimensional conformal radiation therapy in locally advanced XXXX : preliminary results of a phase I dose-escalation study.

@entity1 @entity137 @entity263 @entity5 @entity294 @entity1486
PURPOSE: The acute morbidity of doses of 64.8-75.6 Gy and preliminary observations of late complications and @entity5 response using 3-dimensional conformal radiation therapy in @entity263 are assessed. METHODS AND MATERIALS: 123 @entity1 (Stage A2-12, B1-17, B2-43, C-51) were irradiated to the prostate and seminal vesicles using a 3-dimensional conformal radiation therapy technique. The median follow-up time was 15.2 months. The minimum @entity5 dose was 64.8-66.6 Gy in 49 @entity1 , 70.2 Gy in 46, and 75.6 Gy in 28. @entity137 was scored according to the Radiation Therapy Oncology Group morbidity grading system. RESULTS: This technique of 3-dimensional conformal radiation therapy was well-tolerated with minimal acute morbidity. Only 32% of @entity1 had grade 2 or 3 acute morbidity requiring short-term medication for relief of urinary symptoms or @entity294 . Only one @entity1 (0.8%) has so far developed a severe (grade 4) late complication. Serum @entity1486 concentrations normalized in 67% of @entity1 (64/96) within 1-14 months (median 4.5 months) after treatment and were progressively decreasing at last measurement in an additional 22% (21/96). Abnormal rising @entity1486 levels were observed in 15 @entity1 , 11 of whom have already developed other evidence of relapsing disease. CONCLUSION: Acute @entity137 for the doses tested with this 3-dimensional conformal radiation therapy technique is reduced compared to traditional treatment techniques, and the initial @entity5 response as assessed by @entity1486 measurement is highly encouraging with @entity1486 levels returning to normal in the majority of @entity1 . Based on these results, a further increase of the dose to 81 Gy has been implemented in accordance with the schema of an ongoing Phase I dose-escalation study.
